Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22530482 | 1.00 | MAPT (0.45) | MAPTCASP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16792635 | 0.91 | UHRF1 (0.46) | MAPTCYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL22530049 | 0.87 | KDM4E (0.53) | HTTL3MBTL1MEN1KMT2AUHRF1 | |
| SCHEMBL29351944 | 0.87 | KDM4E (0.53) | HTTL3MBTL1MEN1KMT2AUHRF1 | |
| SCHEMBL29353379 | 0.86 | CYP11B1 (0.49) | MAPTCASP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22530044 | 0.86 | CYP11B1 (0.49) | MAPTCASP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29351849 | 0.85 | MKNK1 (0.48) | MEN1KMT2AUHRF1KDM4ELTA4H | |
| SCHEMBL22529896 | 0.85 | MKNK1 (0.48) | MEN1KMT2AUHRF1KDM4ELTA4H | |
| SCHEMBL22529921 | 0.83 | LRRK2 (0.48) | NPSR1UHRF1KDM4ELTA4HPOLB | |
| SCHEMBL29349917 | 0.83 | LRRK2 (0.48) | NPSR1UHRF1KDM4ELTA4HPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | claimed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | claimed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | claimed |
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | NOTCH1, NOTCH4, NOTCH2 | MAPT 4047/4885CASP1 129/4885CYP1A2 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.